Prescription drugs

Monday

Jim Crotty

Biden must do more to disrupt the fentanyl supply

As 2022 comes to a close, the United States finds itself confronting myriad threats. But there is perhaps no more immediate threat to Americans’ safety and security than illicit drugs. The numbers are staggering. Illicit drugs have killed more than 1 million Americans since the turn of the century, with over 108,000 dying in last 12 months alone. One drug in particular, fentanyl, is now the leading cause of accidental death for adults between the ages of 18 and 45 — more than car accidents, violent crime, and suicide. And the flood of fentanyl into the US shows no signs of abating. In view of this rising ride, the Biden administration has embraced a range of new policies focused on harm reduction and treatment, two historically overlooked areas of American drug control efforts.

Jonathan Bydlak

‘Build Back Better’ could limit access to prescription drugs

Much has been written about the expansiveness of the Biden administration’s signature priority: the Build Back Better Act (BBB). The legislation is projected by the Congressional Budget Office (CBO) to spend more than $1.6 trillion in its attempts to address countless Democratic priorities ranging from climate change to the expansion of Medicaid. One aspect of the bill, however, has attracted far less fanfare than it should have: its impact on the cost of prescription drugs. Provisions in the bill would, among other things, impose rebates on drug manufacturers if prices rise faster than inflation. It’s an idea that sounds great in the current moment of creeping inflation, but is ultimately little more than a market distortion likely to produce an array of adverse consequences.